Pharmacologic Boosting of Atazanavir in Maintenance HIV-1 Therapy The COREYA Propensity-Score Adjusted Study 英文参考文献.docVIP

下载本文档

2
0
约2.82万字
约 6页
2017-05-12 发布于上海
举报
版权申诉

Pharmacologic Boosting of Atazanavir in Maintenance HIV-1 Therapy The COREYA Propensity-Score Adjusted Study 英文参考文献.doc

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Pharmacologic Boosting of Atazanavir in Maintenance HIV-1 Therapy The COREYA Propensity-Score Adjusted Study 英文参考文献

PharmacologicBoostingofAtazanavirinMaintenance HIV-1Therapy:TheCOREYAPropensity-ScoreAdjusted Study LaurentHocqueloux1,PhilippeChoisy2,Gwenae¨lLeMoal3,Franc?oiseBorsa-Lebas4,DavidPlainchamp3, EricLegac5,ThierryPrazuck1,XavierdelaTribonnie`re2,YazdanYazdanpanah2¤,Jean-JacquesParienti6* 1ServicedesMaladiesInfectieusesetTropicales,CentreHospitalierRe′gional,Orle′ans,France,2ServiceUniversitairedesMaladiesInfectieusesetduVoyageur,Ho?pital Gustave-Dron,Tourcoing,France,3ServicedesMaladiesInfectieuses,Ho?pitaldelaMile′trie, Poitiers,France,4ServicedesMaladiesInfectieuses,Ho?pitalCharlesNicolle, Rouen,France,5LaboratoiredeBiologie,CentreHospitalierRe′gional,Orle′ans,France,6Unite′ BiostatistiqueetRechercheClinique,CHUCo?tedeNacre,Caen,France Abstract Background: Among HIV-1 infected patients who achieved virologic suppression, the use of atazanavir without pharmacologic boosting is debated. We evaluated the efficacy and tolerance of maintenance therapy with unboosted atazanavirinclinicalpractice. Methods and Results: This multicenter retrospective cohort study evaluated the efficacy of switching HIV-1-infected patients controlled on triple therapy to unboosted (ATV0, n=98) versus ritonavir-boosted atazanavir (ATV/r, n=254) +2 nucleos(t)idereversetranscriptaseinhibitors.Theprimaryendpointwastimetovirologicfailure(VF,.200copies/mL).ATV groups were compared controlling for potential confounding bias by inverse probability weighted Cox analysis and propensity-score matching. Overall and adjusted VF rates were similar for both strategies. Both strategies improved dyslipidemiaandcreatininemia,withlessjaundiceintheATV0group. Conclusion: In previously well-suppressed patients, within an observational cohort setting, ATV0–based triple-therapy appearedaseffectiveasATV/r-basedtriple-therapytomaintainvirologicsuppression,evenifco-administeredwithTDF, butwasbettertolerated. Citation:HocquelouxL,ChoisyP,LeMoalG,Borsa-LebasF,PlainchampD,etal.(2012)PharmacologicBoostingofAta